Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.1 Million GBP | -13.91% |
| 2022 | 7.09 Million GBP | -16.76% |
| 2021 | 8.52 Million GBP | 219.77% |
| 2020 | 2.66 Million GBP | 153.79% |
| 2019 | 1.04 Million GBP | -54.34% |
| 2018 | 2.29 Million GBP | -4.01% |
| 2017 | 2.39 Million GBP | 128.71% |
| 2016 | 1.04 Million GBP | 222.62% |
| 2015 | 324.65 Thousand GBP | 642.4% |
| 2014 | 43.73 Thousand GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.11 Million GBP | 0.17% |
| 2024 Q2 | 6.11 Million GBP | 0.0% |
| 2023 Q4 | 6.1 Million GBP | 0.0% |
| 2023 Q2 | 7.22 Million GBP | 0.0% |
| 2023 Q1 | 7.22 Million GBP | 1.85% |
| 2023 Q3 | 6.1 Million GBP | -15.48% |
| 2023 FY | 6.1 Million GBP | -13.91% |
| 2022 Q1 | 7.84 Million GBP | -7.96% |
| 2022 Q2 | 7.84 Million GBP | 0.0% |
| 2022 Q4 | 7.09 Million GBP | 0.0% |
| 2022 FY | 7.09 Million GBP | -16.76% |
| 2022 Q3 | 7.09 Million GBP | -9.56% |
| 2021 Q1 | 11.1 Million GBP | 316.82% |
| 2021 FY | 8.52 Million GBP | 219.77% |
| 2021 Q4 | 8.52 Million GBP | 0.0% |
| 2021 Q3 | 8.52 Million GBP | -23.28% |
| 2021 Q2 | 11.1 Million GBP | 0.0% |
| 2020 Q3 | 2.66 Million GBP | -31.25% |
| 2020 Q4 | 2.66 Million GBP | 0.0% |
| 2020 Q1 | 3.87 Million GBP | 269.13% |
| 2020 FY | 2.66 Million GBP | 153.79% |
| 2020 Q2 | 3.87 Million GBP | 0.0% |
| 2019 Q3 | 1.04 Million GBP | -32.31% |
| 2019 Q4 | 1.04 Million GBP | 0.0% |
| 2019 Q2 | 1.55 Million GBP | 0.0% |
| 2019 FY | 1.04 Million GBP | -54.34% |
| 2019 Q1 | 1.55 Million GBP | -32.55% |
| 2018 Q1 | 1.88 Million GBP | -21.37% |
| 2018 Q4 | 2.29 Million GBP | 0.0% |
| 2018 FY | 2.29 Million GBP | -4.01% |
| 2018 Q3 | 2.29 Million GBP | 22.08% |
| 2018 Q2 | 1.88 Million GBP | 0.0% |
| 2017 Q1 | - GBP | -100.0% |
| 2017 FY | 2.39 Million GBP | 128.71% |
| 2017 Q2 | 941.93 Thousand GBP | 0.0% |
| 2017 Q3 | 2.39 Million GBP | 154.32% |
| 2017 Q4 | 2.39 Million GBP | 0.0% |
| 2016 Q4 | 1.04 Million GBP | 0.0% |
| 2016 FY | 1.04 Million GBP | 222.62% |
| 2016 Q2 | 1.26 Million GBP | 0.0% |
| 2015 FY | 324.65 Thousand GBP | 642.4% |
| 2014 FY | 43.73 Thousand GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 84.282% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 15.428% |
| SQZ Biotechnologies Company | 107.18 Million USD | 94.304% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 42.146% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 95.311% |
| Mesoblast Limited | 667.9 Million USD | 99.086% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -8337.633% |
| Genus plc | 1.02 Billion USD | 99.407% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -349.507% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1123.53% |
| Marizyme, Inc. | 22.01 Million USD | 72.265% |
| ContraFect Corporation | 20.67 Million USD | 70.473% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -873.827% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1464.146% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1497.661% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -326.38% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -47.271% |
| MultiCell Technologies, Inc. | 126.22 USD | -4837400.396% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -549.778% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 95.249% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1314.338% |
| Q BioMed Inc. | 3.51 Million USD | -73.684% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 82.643% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -692.31% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2236.942% |
| Biomind Labs Inc. | 73.81 Thousand USD | -8171.438% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 98.681% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 79.657% |
| Skye Bioscience, Inc. | 11.94 Million USD | 48.864% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -84.3% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -122.329% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -211.813% |
| IMV Inc. | 31.33 Million USD | 80.513% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -788.148% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -134.554% |
| GB Sciences, Inc. | 103.44 Thousand USD | -5802.721% |
| Alpha Cognition Inc. | 2.45 Million USD | -149.0% |
| HST Global, Inc. | 1526.00 USD | -400024.05% |
| CSL Limited | 38.02 Billion USD | 99.984% |
| Halberd Corporation | 10.13 Thousand USD | -60169.401% |
| Enzolytics Inc. | 361.7 Million USD | 98.312% |
| Resverlogix Corp. | 8.11 Million USD | 24.758% |
| Affymax, Inc. | 7.44 Million USD | 17.965% |
| SYBLEU INC | 330.46 Thousand USD | -1747.65% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -225.148% |
| argenx SE | 4.54 Billion USD | 99.866% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 78.15% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 87.2% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -26702.568% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 31.771% |
| AVAX Technologies, Inc. | 7.37 Million USD | 17.232% |
| Zenith Capital Corp. | 7410.00 USD | -82300.715% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.82% |
| Ember Therapeutics, Inc. | 184.00 USD | -3318320.109% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1797.383% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2236.165% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.632% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -321.432% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -101.842% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 88.414% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -557.99% |
| BioStem Technologies, Inc. | 14.56 Million USD | 58.065% |
| ONE Bio Corp. | 70.08 Million USD | 91.288% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -10594.457% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -264224.372% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -518.026% |
| Agentix Corp. | 261.39 Thousand USD | -2235.914% |
| LadRx Corporation | 2.3 Million USD | -164.567% |
| Cell Source, Inc. | 195.17 Thousand USD | -3028.484% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1170.587% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1626.697% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1626.697% |
| NovAccess Global Inc. | 62.24 Thousand USD | -9708.979% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -854.559% |
| Itoco Inc. | 1.4 Million USD | -336.113% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -6283.112% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -5660.276% |
| Kadimastem Ltd | 2.3 Million USD | -165.004% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -7896.821% |
| CytoDyn Inc. | 11.13 Million USD | 45.17% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -4170.691% |
| Mobile Lads Corp. | 52.00 USD | -11742001.923% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -34049.29% |
| Qrons Inc. | 420.00 USD | -1453684.048% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1484.008% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1005.9% |
| Rebus Holdings, Inc. | 5000.00 USD | -122017.86% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1391.345% |
| International Stem Cell Corporation | 5.39 Million USD | -13.282% |
| Bioxytran, Inc. | 137.63 Thousand USD | -4336.197% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 59.299% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 63.171% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -7628.978% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -606.147% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 18.772% |
| Neutra Corp. | 2851.00 USD | -214066.713% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 81.158% |
| PureTech Health plc | 693.97 Million USD | 99.12% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 24.349% |
| IXICO plc | 15.84 Million USD | 61.462% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 26.275% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.091% |
| CSL Limited | 38.02 Billion USD | 99.984% |
| Cellectis S.A. | 333.99 Million USD | 98.172% |